• Triple-action formula: Glimepiride stimulates insulin release, Metformin reduces liver glucose production and improves sensitivity, Voglibose delays carbohydrate absorption to control post-meal spikes.
• Sustained Release (SR) Metformin for steady blood sugar management throughout the day.
• Trusted Cipla quality for Type 2 diabetes control when diet and exercise alone aren't enough.

Glimda MV 1 Tablet is a combination oral anti-diabetic medication formulated with Glimepiride 1mg and Metformin (Sustained Release) 500mg, designed for effective management of Type 2 Diabetes Mellitus.

This dual-action formula works through two complementary mechanisms:

• Glimepiride stimulates the pancreas to release insulin, helping lower blood sugar levels.
• Metformin SR improves insulin sensitivity and reduces glucose production in the liver while decreasing glucose absorption from the intestine.
• Together, they provide better glycemic control than single-drug therapy, especially in patients whose blood sugar levels are not adequately controlled by diet, exercise, or monotherapy.
• Glimda MV 1 Tablet helps control both fasting and post-meal blood glucose levels and reduces the risk of long-term complications such as kidney damage, nerve problems, eye disorders, and cardiovascular issues.

It is usually taken once daily with meals (preferably breakfast), or as prescribed by your healthcare provider. Regular monitoring of blood sugar and adherence to lifestyle modifications are essential for optimal results.

Important: This medicine is intended for Type 2 Diabetes only and should be used strictly under medical supervision.

Key Features:

• Composition: Glimepiride 1mg + Metformin HCl 500mg (SR) + Voglibose 0.2mg per tablet.
• Sustained-release technology minimizes GI upset and maintains consistent efficacy.
• Pack: Typically 10 tablets per strip from Cipla Ltd..

Benefits:

• Lowers fasting and postprandial blood sugar to reduce diabetes risks.
• Improves insulin response and sensitivity for long-term management.
• Reduces cardiovascular mortality risk in Type 2 diabetics.

Active Ingredients:

• Glimepiride IP 1mg
• Metformin Hydrochloride IP 500mg (Sustained Release)

Excipients (may include):

• Povidone.
• Microcrystalline Cellulose.
• Magnesium Stearate.
• Hypromellose (for sustained release).
• Lactose (if applicable).
• Colouring Agents.

• Swallow whole with water, with or immediately before meals, at the same time daily.
• Follow doctor's dosage; do not crush, chew, or skip doses.
• Monitor blood sugar regularly; adjust based on levels and response.

• Common side effects: Hypoglycemia, nausea, diarrhea, headache, taste changes.
• Avoid in Type 1 diabetes, ketoacidosis, severe kidney/liver issues, pregnancy, or breastfeeding.
• Limit alcohol; carry sugar source for low blood sugar; inform doctor of other meds.

• Dosage Form: Tablet (Sustained Release Combination).
• Strength: Glimepiride 1mg + Metformin SR 500mg.
• Pack Size: Strip of 10 Tablets.
• Drug Category: Sulfonylurea + Biguanide Combination.
• Route of Administration: Oral.
• Prescription Required: Yes.
• Indication: Type 2 Diabetes Mellitus.
• Suitable For: Adults only (as prescribed).
• Storage Instructions: Store below 25°C in a dry place. Protect from moisture and direct sunlight.

What is Glimda-MV 1 used for?
It manages Type 2 diabetes by controlling blood sugar via multiple mechanisms.

How should I take it?
With meals, whole, as prescribed—never exceed dose.

What are side effects?
Nausea, low sugar, GI upset; seek help for severe symptoms.

Is it safe in pregnancy?
No—consult doctor.

Does it cause weight gain?
Possible; monitor with diet.

Name: Cipla Ltd.
Address: Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400013.